Abstract: Statins exert a number of beneficial effects on endothelial function and atherosclerotic plaque, modulating oxidative stress and inflammation, with subsequent, well documented, primary and secondary prevention of coronary artery disease. Periprocedural myocardial infarction and contrast induced nephropathy, after percutaneous coronary intervention (PCI), are associated with a worse outcome on long term follow-up. In the ARMYDA study, pretreatment with statins before elective PCI reduces periprocedural myocardial infarction in patients with stable angina. Moreover, the ARMYDA ACS was the first randomized, prospective trial that demonstrated that an acute loading with a high dose of atorvastatin prevents myocardial damage in patients with unstable syndromes undergoing early (<48 hours) coronary angiography and consequent angioplasty. Statins could also have beneficial effects by reducing expression of adhesion molecules in endothelial cells (ICAM-1 and E-Selectin) as demonstrated in the ARMYDA-CAMS study. Furthermore, patients receiving statins at the time of procedure show a significantly reduced incidence of contrast-induced nephropathy. All this evidence may strongly influence the clinical practice of an interventional cardiologist.
Statins inhibit hepatic 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase with consequent suppression of cholesterol biosynthesis. The benefits of statins are well documented in primary and secondary prevention for coronary artery disease (Scandinavian Simvastatin Survival Study 1994; Sacks et al. 1996; LIPID 1998) . Besides their lipid-lowering properties, statins exert a number of protective effects, involving improvement of endothelial function, stabilization of atherosclerotic plaque, decrease of oxidative stress and inflammation, and inhibition of thrombogenic response (Morikawa et al. 2002; Davignon 2004) . Their benefit has been largely demonstrated also in the setting of percutaneous coronary interventions (PCI) by the prevention of periprocedural myocardial and renal damage, both complications related to an inflammatory pathogenesis.
Statins and prevention of periprocedural myocardial infarction
Myocardial infarction (MI) after PCI is associated with increased mortality rate during follow-up (Ioannidis et al. 2003) . The amount of cardiac markers released is proportional to infarct size and is related with significantly higher incidence (Turer et al. 2005) . Despite improvements in operative technique, post-procedural elevation in cardiac enzymes remains relatively frequent, occurring in up to 30-40% of patients (Abdelmeguid et al. 1996; Brener et al. 2002) . Different treatment strategies have been developed to obtain a reduction of this complication. Nitrate infusion (Kurz et al. 2000) , intracoronary beta-blockers (Wang et al. 2003) , Gp IIb/IIIa inhibitors (The EPISENT Investigators 1998) and adenosine (Desmet et al. 2002) have been proposed, but only Gp IIb/IIIa inhibitors have been used in current clinical practice.
Several observational prospective and retrospective studies demonstrated decreased periprocedural MI after statin administration. Herrmann et al. [2002] demonstrated that patients in treatment with different statins for more than one week, undergoing PCI, had a lower incidence of MI (creatine kinase (CK)>3 times normal limits, 0.4% vs 6%; p = 0.03) compared with the non statin group. Chan et al. [2002] demonstrated in a larger series of patients (n = 5052) that statins treatment at the time of PCI was associated with a lower 30-day and 6-month all cause mortality. In 1552 patients undergoing coronary angioplasty, a lower incidence of postprocedural MI (5.7% vs 8.1%; p = 0.038) and 1-year mortality (3.4% vs 6.9%; p = 0.003) was observed in patients who were on statins at the time of procedure (Chan et al. 2004) . However, none of these studies were randomized, even if prospective.
The ARMYDA study was the first randomized, placebo-controlled, double-blind, prospective study that demonstrated a beneficial effect of statins in preventing myocardial damage after coronary angioplasty (Pasceri et al. 2004 ). This study enrolled 153 patients with chronic stable angina undergoing elective PCI randomized to placebo (n = 77) and atorvastatin 40 mg (n = 76), starting 7 days before the planned intervention. A significant reduction of postprocedural MI (defined as an increase of CK-MB>2 times the upper normal limit) was detected in patients receiving atorvastatin (5% vs 18%; p = 0.025) (Figure 1 ). Also considering the absolute values of cardiac markers, there were significant differences between the two groups (CK-MB 35% vs 12%, p = 0.001; Tn I 20% vs 48%, p = 0.0004, myoglobin 22% vs 51%, p = 0.0005). At 1 month follow-up, no other cardiac event was observed in the two groups and the 30-day composite end point (death, myocardial infarction and repeat coronary revascularization; 5% vs 18%; p = 0.025) was entirely ascribed to the reduction of periprocedural MI. Multivariate logistic regression analysis demonstrated that pretreatment with atorvastatin was independently associated with lower risk of periprocedural CK-MB increase (OR 0.19; 95% CI 0.05 to 0.57).
In patients with non-ST segment elevation acute coronary syndromes (ACS), results from randomized trials on early use of statins have yielded conflicting data: the MIRACL study showed that atorvastatin 80 mg given 24-96 hours after admission for an unstable syndrome produced a significant reduction in the recurrence of myocardial ischemia (Schwartz et al. 2001) . Indeed, a recent metanalysis from 12 randomized trials comparing early (<14 days) statin therapy versus placebo or usual care after an ACS, reported no clinical benefit in the occurrence of death, myocardial infarction or stroke at 4 months follow-up in patients receiving statins (Briel et al. 2006) . Nevertheless, all these findings were detected in patients undergoing conservative strategy, without coronary intervention. Chang et al. [2004] evaluated the impact of pre-treatment with statins in patients with ACS in the setting of coronary intervention. They observed that patients who were on statins had a lower incidence of periprocedural myocardial necrosis compared to patients who were not on statins (2% vs 19%, p = 0.04), with a significant better event free survival at 6 months (19% vs 31%; p = 0.015). However, the ARMYDA ACS was the first randomized, prospective, double-blind clinical trial that investigated the possible beneficial effect of an acute loading with a high dose of atorvastatin in patients with unstable syndromes undergoing early (<48 hours) coronary angiography and consequent angioplasty (Patti et al. 2007) . Patients (n = 171) were randomized to receive placebo (n = 85) or atorvastatin (n = 86, 80 mg loading dose given a mean of 12 hours before coronary angiography, with a further 40 mg dose approximately 2 hours before the procedure). The primary composite end point, 30 day incidence of major adverse cardiac events (death, myocardial infarction, target vessel revascularization) occurred in 5% of patients in the atorvastatin group and in 17% of those not pre-treated (p = 0.01) (Figure 2) , with an incidence of post procedural MI of 5% and 15% ( p = 0.04), respectively. Multivariate analysis indicated an 88% risk reduction of MACE Review (OR 0.12, 95% CI 0.05 to 0.50; p = 0.004) and a 70% risk reduction of periprocedural myocardial infarction at 1 month in the atorvastatin group (Figure 3 ): according to these data, 10 patients should be treated with atorvastatin to avoid 1 case of myocardial infarction. Also the incidence of the secondary end point, prevalence of patients with post-procedural elevation of creatine kinase MB and troponin I above the upper normal limit, was significantly lower in patients receiving high dose of statins before PCI (CK-MB 7% vs 27%, p = 0.001; Tn I 41% vs 58%, p = 0.039).
The mechanisms of statins benefit in reducing myonecrosis in patients undergoing PCI is not completely elucidated, but they could be related to the 'pleiotropic effects' of these drugs. These effects may also start acutely after drug administration as demonstrated in different in vivo and in vitro experiences and before their lipid-lowering effects (Wassmann et al. 2003; Hinoi et al. 2005) . In addition to plaque stabilization, as shown by reduction of matrix metalloproteinase secretion (Bellosta et al. 1998) , statins may have anti-thrombotic effects, by reducing platelet CD40L expression, as well as production of prothrombin fragment F1+2 (Sanguigni 2005) . Moreover statins have been demonstrated to attenuate inflammatory markers such as C-reactive protein (CRP) after acute coronary syndromes (Kinlay et al. 2003) . In the ARMYDA ACS study, atorvastatin pre-treatment has reduced post-procedural levels of CRP in patients with higher baseline levels of such marker (Patti et al. 2007 ). Finally, statins have been shown to reduce adhesion molecule expression in endothelial cells via nitric oxide pathway (Xenos et al. 2005) . These experimental data were confirmed by the ARMYDA-CAMS study (Patti et al. 2006 ), a substudy of ARMYDA trial. In this study, vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1) and E-selectin plasma levels were blindly measured in 38 patients pre-treated with atorvastatin undergoing PCI and in 38 patients not pre-treated at randomization (i.e., 7 days before procedure), immediately before the angioplasty, and after 8 and 24 hours. Atorvastatin significantly attenuated ICAM-1 and E-selectin levels after PCI.
On the basis of this evidence, the antiinflammatory effects of statins may lead to an improvement in microvessel coronary circulation and endothelial function, with a reduction of thromboembolic events and consequent myocardial protection from procedural ischemic damage that translates into clinical early and long-term better outcome both in acute coronary syndromes and in stable coronary artery disease.
Statins and prevention of contrast induced nephropathy
Contrast induced nephropathy (CIN) is a recognized complication after PCI and has been associated with an increased risk of early and late cardiovascular events both in patients with pre-existing chronic renal failure and in patients with normal baseline serum creatinine (SCr) levels (Gruberg et al. 2000; Rihal et al. 2002; Lindsay et al.2003) . Although the pathogenesis of CIN is not completely known, inflammatory mechanisms and oxidative stress may be involved (Murphy et al. 2000) ; thus, statins could have a significant benefit in this setting by their anti-inflammatory effects and improvement of endothelial function. Results by Khanal et al. [2005] , from a large insurance database, have shown that statin treatment is associated with a reduced incidence of CIN after PCI. An observational prospective study by our group confirmed these findings (Patti et al. 2008) . The study population consisted of 434 consecutive patients undergoing PCI, divided into statin-treated patients (n = 260) and statin-naïve patients (n = 174) at the time of intervention. Patients receiving statins had a significantly lower incidence of CIN (3% vs 27% in patients without statins; p < 0.0001) (Figure 4 ), defined as a post-procedural increase in serum creatinine of ≥0.5 mg/dl or >25% from baseline, corresponding to a 90% risk reduction (OR 0.10, 95% CI 0.02 to 0.18; p = 0.0001), and had higher post-procedural creatinine clearance (80 ± 25 vs 65 ± 19 mL/min; p < 0.0001). Multivariate analysis showed that statin pre-treatment was an important predictor of decreased incidence of CIN (OR 0.10, 95% CI 0.02 to 0.018, p = 0.0001) and this benefit was maintained in all subgroups, except for the patients with a baseline creatinine clearance <40 ml/min (OR 0.42, 95% CI 0.1 to 2.8; p = 0.37), probably related to the multiple non-eversible mechanisms of advanced renal dysfunction. At four year clinical follow-up, the occurrence of cardiovascular events (cardiac death, MI, or repeat coronary revascularization) was significantly reduced in patients receiving statins at the time of procedure (6% vs 36%, p < 0.0001). Actuarial life-table analysis ( Figure 5) showed that 4-year event free survival was obviously best in patients treated with statins and no CIN (95%, p ≤ 0.015 vs other groups) and worst in statin naïve patients with CIN (53%, p ≤ 0.018 vs other groups); interestingly, survival of statin-treated patients who developed CIN was similar to that of statin-naïve patients who did not develop this complication (72% vs 71%), demonstrating that prevention of CIN by statins translates into significant improved outcome at long-term follow-up.
The beneficial effect of statins on CIN prevention may be explained by multiple mechanisms. Statins could modulate the kidney hypoperfusion after contrast media administration by a downregolation of angiotensin receptors and a decreased synthesis of endothelin (Hernandez-Perera et al. 1998; Ichiki et al. 2001) . Furthermore, toxic damage on the tubular cells by oxygen free radicals and proinflammatory cytokines may be decreased by anti-inflammatory effects of statins that inhibit the nuclear factor κB, a transcription factor of genes encoding for proinflammatory molecules (Bonetti et al. 2003) . However, pathogenesis of late adverse cardiac events in patients undergoing successful PCI that developed CIN is unclear as is the mechanisms of statins on long-term improved outcome. The occurrence of renal dysfunction after contrast media administration may represent a marker of multisystem atherosclerosis responsible for late cardiac events and statins could prevent these by the same mechanisms that exerted during PCI.
Conclusions
Periprocedural myocardial infarction and contrast induced nephropathy after percutaneous coronary intervention are associated with a worse outcome on long term follow-up. Pretreatment with statin before elective PCI reduces periprocedural myocardial injury in patients with stable angina. Moreover, short-term statin administration before coronary stenting also improves clinical outcome in patients with acute coronary syndromes. Finally, patients receiving statins at the time of procedure show a significantly reduced incidence of contrast-induced nephropathy. All this evidence strongly supports routine utilization of statins as adjuvant pharmacological therapy before percutaneous coronary revascularization.
